title: Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations.
authors.forename: Ludovic
authors.initials: L
authors.lastname: Lacroix
authors.forename: Patricia
authors.initials: P
authors.lastname: Pautier
authors.forename: Pierre
authors.initials: P
authors.lastname: Duvillard
authors.forename: Nelly
authors.initials: N
authors.lastname: Motté
authors.forename: Patrick
authors.initials: P
authors.lastname: Saulnier
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Bidart
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Soria
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002277:Carcinoma / Q000188:drug therapy* / Q000235:genetics*; D004252:DNA Mutational Analysis; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000235:genetics* / Q000502:physiology; D005260:Female; D000077156:Gefitinib; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D017239:Paclitaxel / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D011799:Quinazolines; D016190:Carboplatin; D066246:ErbB Receptors; D017239:Paclitaxel; D000077156:Gefitinib